|Study Name (Ref. #)||NCT||n||Study Findings||Per-Vessel||Per-Patient|
|DISCOVER-FLOW (29)||NL||103||Diagnostic performance trial evaluating first version of FFRCT (version 1.0)||88%, 74%||82%, 92%||93%, 85%||81%, 91%|
|DeFACTO (30)||NCT01233518||252||Diagnostic performance trial evaluating older version of FFRCT (version 1.2)||83%, NR||78%, NR||90%, 67%||54%, 84%|
|NXT (31)||NCT01757678||254||Diagnostic performance trial evaluating latest generation version of FFRCT (version 1.4)||84%, 61%||86%, 95%||86%, 65%||79%, 93%|
|RIPCORD-FFRCT (35)||NL||200||Evaluation of the diagnostic impact of FFRCT to guide medical versus invasive therapies|
|PLATFORM (41)||NCT01943903||580||Sequential longitudinal cohort study demonstrating 61% reduction in CATH normalcy for FFRCT-guided vs. coronary CTA-guided care|
CABG = coronary artery bypass graft; DeFACTO = Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography; DISCOVER-FLOW = Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve; FFRCT = coronary computed tomography angiography–derived fractional flow reserve; NCT = National Clinical Trial; NL = not listed; NPV = negative predictive value; NR = not reported; NXT = Analysis of Coronary Blood Flow Using CT Angiography: Next Steps; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; PLATFORM = Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts; PPV = positive predictive value.